Results 41 to 50 of about 150,706 (165)

Acute Leukemia and Pregnancy

open access: yesEuropean Journal of Inflammation, 2007
The combination of acute leukemia and pregnancy is infrequent. It is estimated to occur in less than 1 in 75,000 pregnancies. Maternal and fetal outcomes have improved substantially in recent years.
V. Karagiannis   +6 more
doaj   +1 more source

Quantitative PCR for HTLV‐1 provirus in adult T‐cell leukemia/lymphoma using paraffin tumor sections [PDF]

open access: bronze, 2016
Junki Kato   +9 more
openalex   +1 more source

Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)

open access: yesJournal of Hematology & Oncology, 2017
Background Acute myeloid leukaemia (AML) with 17p abnormalities (abn(17p)) carries a very poor prognosis due to high refractoriness to conventional chemotherapy, and allogeneic stem cell transplantation (allo-SCT) appears as the only potential curative ...
Xavier Poiré   +15 more
doaj   +1 more source

Targeting survivin in leukemia

open access: yesOncology Reviews, 2011
Survivin, a member of the inhibitors of apoptosis family of proteins, is one of the most frequently upregulated transcripts in solid tumors and hematopoietic malignancies.
Bing Z. Carter, Michael Andreeff
doaj   +2 more sources

Identifying long-term survivors and those at higher or lower risk of relapse among patients with cytogenetically normal acute myeloid leukemia using a high-dimensional mixture cure model

open access: yesJournal of Hematology & Oncology
Patients with cytogenetically normal acute myeloid leukemia (CN-AML) may harbor prognostically relevant gene mutations and thus be categorized into one of the three 2022 European LeukemiaNet (ELN) genetic-risk groups.
Kellie J. Archer   +13 more
doaj   +1 more source

Deep Dive into Targeted Therapies: Understanding IDH1-Mutant AML Treatments [Podcast]

open access: yesBlood and Lymphatic Cancer: Targets and Therapy
Amer M Zeidan,1,* Courtney DiNardo2,* 1Department of Internal Medicine, Yale School of Medicine, Yale University, New Haven, CT, USA; 2Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA*These authors contributed equally to this ...
Zeidan AM, DiNardo C
doaj  

Home - About - Disclaimer - Privacy